Clozapine‐induced myocarditis: Follow‐up for 3.5 years after successful retrial
| Autor: | Yutaka Hosoda, Tsutomu Aoki, Yuji Otsuka, Keita Idemoto, Yukitsugu Imamura |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty Myocarditis medicine.medical_treatment Population Case Report Case Reports 01 natural sciences retrial 03 medical and health sciences 0302 clinical medicine Internal Medicine medicine 030212 general & internal medicine 0101 mathematics education Antipsychotic Clozapine education.field_of_study clozapine business.industry Mortality rate 010102 general mathematics medicine.disease Schizophrenia life expectancy Life expectancy myocarditis Geriatrics and Gerontology Family Practice business sodium valproate medicine.drug |
| Zdroj: | Journal of General and Family Medicine |
| ISSN: | 2189-7948 |
| DOI: | 10.1002/jgf2.239 |
| Popis: | Schizophrenia patients have significantly lower life expectancy than the general population. Clozapine is the most effective antipsychotic to reduce the mortality rate in these patients. Here, we report a schizophrenic patient with clozapine‐induced myocarditis and successful retrial. In the first trial, clozapine was discontinued due to myocarditis. In the second trial, the titration rate was slower, and sodium valproate was not coadministered with clozapine. The patient has not developed myocarditis over 3.5 years of observation. It may be possible to take clozapine for a long time even after clozapine‐induced myocarditis, and thus improve the life expectancy of schizophrenia patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text